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Aqueductal cerebrospinal fluid pulsatility in healthy individuals is 
affected by impaired cerebral venous outflow 
 
Abstract 
Purpose: To investigate cerebrospinal fluid (CSF) dynamics in the aqueduct 
of Sylvius (AoS) in chronic cerebrospinal venous insufficiency (CCSVI) 
positive and negative healthy individuals using cine phase contrast imaging. 
Materials and Methods: Fifty one healthy individuals [32 CCSVI negative 
and 19 age-matched CCSVI positive subjects] were examined using Doppler 
sonography (DS). Diagnosis of CCSVI was established if subjects fulfilled ≥2 
venous hemodynamic criteria on DS. CSF flow and velocity measures were 
quantified using a semi-automated method and compared with clinical and 
routine 3T MRI outcomes. 
Results: CCSVI was associated with increased CSF pulsatility in the AoS. 
Net positive CSF flow was 32% greater in the CCSVI positive group 
compared with the CCSVI negative group (p=0.008). This was accompanied 
by a 28% increase in the mean aqueductal characteristic signal (i.e. the AoS 
cross-sectional area over the cardiac cycle) in the CCSVI positive group 
compared with the CCSVI negative group (p=0.021).  
Conclusion: CSF dynamics are altered in CCSVI positive healthy individuals, 
as demonstrated by increased pulsatility. This is accompanied by 
enlargement of the AoS, suggesting that structural changes may be occurring 
in the brain parenchyma of CCSVI positive healthy individuals. 
 
Keywords: CSF dynamics, CCSVI, cerebral venous outflow, aqueduct of 
Sylvius, healthy individuals, lateral ventricle volume 
 
Introduction 
Recently it has been suggested that abnormalities of the venous system might 
be associated with multiple sclerosis (MS) (1-5). This has led some to 
postulate the concept of chronic cerebrospinal venous insufficiency (CCSVI) 
as an indicator of neurovascular pathology. However, a number of studies 
have shown that CCSVI also occurs in healthy individuals with unknown 
pathology (4,6,7), leading many to question its validity (8-13). Criticism has 
been levelled at the concept of CCSVI because it implies an abnormal 
cerebral venous drainage system. In reality, humans exhibit great variability in 
the venous system, making it difficult to differentiate what is normal from what 
is abnormal (14,15).  Hydrodynamic analysis of the cerebral venous outflow 
has shown that patients with MS exhibit increased hydraulic resistance to 
extracranial venous blood flow compared with healthy controls (16,17). 
Furthermore, several studies have shown that MS is associated with 
increased cerebrospinal fluid (CSF) pulsatility in the aqueduct of Sylvius (AoS) 
(18-20). Although Zamboni et al (19) observed increased CSF pulsatility in 
MS patients diagnosed with CCSVI, it is not known if the two phenomena are 
linked. Indeed, it may be that increased CSF pulsatility in MS patients is 
primarily due to ventricular enlargement associated with brain atrophy (21,22). 
 
In a similar manner to individuals with MS, patients with normal pressure 
hydrocephalus (NPH) appear to exhibit increased AoS pulsatility (23-28). 
Given that NPH is thought to be associated with venous hypertension in the 
dural sinuses (29,30), it may be that impaired cerebral venous outflow alters 
the dynamics of the intracranial CSF system, irrespective of any pathology. In 
order to test this hypothesis, we undertook a study involving 51 age-matched 
healthy individuals with no family history of MS.  The aim of the study was 
simply to evaluate whether or not CCSVI is associated with changes in the 
dynamics of the intracranial CSF system in healthy individuals without any 
known neurological condition. 
 
 
Materials and methods 
Patient population 
Fifty one healthy individuals [32 CCSVI negative and 19 CCSVI positive] were 
enrolled in this study. They were part of a larger study that investigated the 
relationship between CCSVI and conventional MRI characteristics in MS 
patients and healthy individuals (31).  Inclusion criteria were: age 18 to 75 
years, undergoing Doppler sonography (DS) and MRI scan with cine phase 
contrast imaging for CSF flow estimation. Relevant information relating to: 
vascular risk factors [body mass index (BMI), hypertension, heart disease and 
smoking] was also collected. The individuals also needed to qualify on a 
health screening questionnaire containing information about medical history 
(illnesses, surgeries, medications, etc.) and meet the health screen 
requirements for MRI on physical examination, as previously described 
(4,31,32).  Exclusion criteria were: pre-existing medical conditions known to 
be associated with brain pathology (e.g. cerebrovascular disease, positive 
history of alcohol abuse, etc.), history of cerebral congenital vascular 
malformations, type 1 diabetes, or pregnancy.  
 
All participants underwent clinical, DS and MRI examinations. The study was 
approved by the local Institutional Review Board and informed consent was 
obtained from all subjects. 
 
 
Doppler sonography 
Extra- and trans-cranial DS was performed on a color-coded DS scanner 
(MyLab 25; Esaote-Biosound, Irvine, California) equipped with a 5.0- to 10-
Mhz transducer to examine venous return in the internal jugular veins (IJVs) 
and vertebral veins (VVs). The DS examination was performed by 2 trained 
technologists who were blinded to the subjects’ characteristics. The detailed 
scanning protocol and validation were recently reported (4,33). Briefly, the 
following 5 VH (venous hemodynamic) parameters indicative of CCSVI were 
investigated: 1) Reflux/bidirectional flow in the IJVs and/or in the VVs in sitting 
and in supine positions, defined as flow directed towards the brain for a 
duration of >0.88 s; 2) Reflux/bidirectional flow in the deep cerebral veins 
defined as reverse flow for a duration of 0.5 s in one of the intra-cranial veins; 
3) B-mode abnormalities or stenoses in IJVs. IJV stenosis is defined as a 
cross-sectional area (CSA) of this vein ≤0.3 cm2; 4) Flow that is not Doppler-
detectable in IJVs and/or VVs despite multiple deep breaths, and 5) Reverted 
postural control of the main cerebral venous outflow pathway by measuring 
the difference of the CSA of the IJVs in the supine and upright positions. A 
subject was considered CCSVI-positive if ≥2 VH criteria were fulfilled, as 
previously proposed (1). We also calculated the VH insufficiency severity 
score (VHISS) as a measure of CCSVI severity (19). The overall VHISS score 
is the weighted sum of the scores contributed by each individual VH criterion 
(i.e. VHISS = VHISS1 + VHISS2 + VHISS3 + VHISS4 + VHISS5). The VHISS 
score is an ordinal measure of the overall extent and number of VH flow 
pattern anomalies, with a higher value of VHISS indicating a greater severity 
of VH flow pattern anomalies. The minimum possible VHISS value is 0 and 
the maximum 16. 
 
 
MRI acquisition and analysis 
All subjects were examined on a 3 Tesla GE Signa Excite HD 12.0 Twin 
Speed scanner (General Electric, Milwaukee, WI). All sequences were run on 
an 8-channel head and neck (HDNV) coil.  All analyses were performed in a 
blinded manner.  
 
MRI sequences included 3D high resolution (HIRES) T1-WI using a fast 
spoiled gradient echo (FSPGR) with magnetization-prepared inversion 
recovery (IR) pulse and cine phase contrast imaging for CSF flow estimation. 
Pulse sequence characteristics for 3D T1 sequence were: a 256 x 256 matrix 
and a 25.6 cm field of view (FOV) for an in-plane resolution of 1 x 1 mm2 with 
a phase FOV (pFOV) of 75% and one average.  Sequence specific 
parameters were: 1-mm thick slices with no gap, echo time/inversion 
time/repetition time (TE/TI/TR)=2.8/900/5.9 ms, flip angle (FA)=10°.  On 3D 
t1, the SIENAX cross-sectional software tool (version 2.6; 
http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/SIENA) was used to estimate normalized 
brain volume (NBV) and normalized lateral ventricular volume (NLVV), as 
previously described (34). Prior to segmentation, the 3D T1 WI was modified 
using an in-house developed inpainting tool to avoid the impact of T1 
hypointensities.  
 
 
CSF flow quantification was performed using a single slice cine phase-
contrast velocity-encoded pulse-gated gradient echo sequence (cine PC) with 
an TE/TR of 7.9/40 ms, a slice thickness of 4 mm, a velocity encoding of 20 
cm/s, and 32 phases acquired corresponding to the cardiac cycle (18). Other 
relevant scan parameters included a FA of 20°, FOV 10.0 cm, and a phase 
FOV of 100%. A sagittal T2-weighted fast SE sequence was also acquired as 
a localizer for the cine PC prescription, as previously described, with the cine 
PC sequence prescribed as an oblique axial slice through the AoS (18).  All 
subjects underwent the MRI exam during the same time of day (in the 
afternoon hours) to control for circadian variation. The cine PC sequence was 
acquired with the AoS in the center of the FOV, such that the wrap around 
artifact was present in the edges of the FOV, but did not overlap with the 
desired ROI. To ensure reproducibility, repeat scans were performed as 
described in Magnano et al (18).   
 
 
Cine phase contrast image analysis 
The net positive and net negative flows (NPF and NNF), together with the net 
flow (NF = NNF + NPF) were calculated, as previously described (18). Briefly, 
CSF flow data was processed using GE ReportCard software (version 3.6; 
General Electric, GE, Milwaukee, WI) and positive and negative velocities 
over all 32 phases were recorded. A semi-automated minimum area of 
contour change (MACC) program was used to correct the ROIs for each 
phase, as previously described (18). MACC automatically determined the 
edges of an ROI by selecting a surrounding iso-contour curve which marks 
the steepest overall gradient of image intensity values, with sub-voxel 
accuracy. NPF and NNF were calculated using only the phases which have 
positive and negative velocities, respectively (18). The respective CSF flow 
rates were calculated by multiplying the measured CSF velocities by the 
measured CSA of the AoS over the cardiac cycle. CSF flow measures are 
presented in microliters per beat (µL/beat, 1µL = 1mm3), while CSF velocity 
measures are presented in cm/s. CSF flow direction was calculated based on 
slice prescription such that flow through the AoS out of the slice (during 
diastole, towards the third ventricle) was given as positive, whereas flow into 
the slice (during systole, towards the fourth ventricle) was negative, as 
described previously (18). 
 
Statistical analysis 
Analysis was undertaken using the Statistical Package for Social Sciences 
(SPSS, IBM, Armonk, New York, USA) and in-house algorithms written in 
Matlab (Mathworks, Natick, Mass). The demographic and clinical differences 
between the CCSVI positive and negative groups were tested using the chi-
square test and Student’s t-test, while analysis of the MRI data was 
undertaken using the Mann–Whitney rank sum test. CSF flow differences 
between the study groups were evaluated using the Mann–Whitney rank sum 
test. In order to assess the impact of a CCSVI diagnosis on aqueductal 
behavior, for each subject we divided the sequential CSF flow signal by the 
sequential CSF velocity signal, to produce the aqueductal characteristic signal 
(ACS), shown in Figure 3, which represents the changes in the AoS cross-
sectional area throughout the cardiac cycle. This is identical to the cross 
sectional area of the AoS as calculated by MACC at each instantaneous 
phase of the cardiac cycle. Values of p<0.05 using a two-tailed test were 
considered statistically significant after the Benjamini-Hochberg (35) 
correction for multiple comparisons was applied. 
 
The following analysis techniques were also employed: 
 
1. Correlation matrices (Pearson’s r) were computed for the CCSVI 
positive and negative groups, to identify changes in the 
relationships between the variables within the dataset. Statistical 
significance was determined using a two-tailed Fisher r-to-z 
transformation. 
2. Singular value decomposition (SVD) analysis was used to visualize 
the differences between the CCSVI positive and negative groups, 
and also to generate sensitivity and specificity scores. 
 
In order to perform singular value decomposition (SVD) the data, we created 
a (m  3) matrix, Z, containing the data for both the CCSVI negative and 
positive groups. The columns of the Z matrix comprised the variables NNF, 
NPF and NLVV, which we mean-adjusted and standardized to unit variance. 
SVD was then performed on Z as follows: 
 
TVSUZ ..        (1) 
 
where: U is a (m  3) left singular vector (LSV) matrix with identical 
dimensions to Z; S is a (3  3) singular value (SV) matrix; and V is a (3  3) 
right singular vector (RSV) matrix. In U, the columns (LSVs) are orthogonal 
composites of the three original variables in Z, with the rows equating to the 
participants in the study. Plotting the individual LSVs against each other 
produced scatter plots of the orthogonalized data. By identifying the elements 
of U that belong to the CCSVI negative and positive cohorts, respectively, it 
was possible to perform cluster analysis. 
 
Results 
Demographic and clinical characteristics 
Table 1 shows demographic, clinical and conventional MRI characteristics of 
the CCSVI positive and negative groups. There were no significant age- or 
sex- differences between the CCSVI positive and negative subjects, with no 
significant difference between the NBV. No significant differences were found 
between the two groups regarding: BMI; hypertension; heart problems; and 
smoking habit. There were however significant differences for VH criteria 
score (p<0.0001) and VHISS score (p<0.0001) between the CCSVI positive 
and negative cohorts. 
 
Time series analysis 
Figures 1 and 2 present average time series signals for CSF flow and velocity 
in the AoS over a cardiac cycle. From these it can be seen that the CCSVI 
positive individuals exhibit increased pulsatility, in both the flow and velocity 
signals. While there was no significant difference between the CSF velocity 
signals for the two groups, the peak positive flow rate (towards the lateral 
ventricles) was significantly greater (p=0.023) in the CCSVI positive group 
compared with the negative group. Similarly, the mean ACS signal, shown in 
Figure 3, was significantly greater (p=0.021) in the CCSVI positive group 
compared with the negative group.    
 
Univariate analysis 
Table 2 shows the quantitative assessment and univariate analysis results for 
the respective MRI variables, with the subjects grouped according to CCSVI 
status. This reveals that although NLVV was increased in the CCSVI positive 
group, this increase was not significant. A statistically significant 32% increase 
in CSF NPF towards the lateral ventricles (p=0.008) was observed in the 
CCSVI positive group. A similar increase was observed in NNF towards the 
spine in the CCSVI positive individuals, but this did not reach significance. 
Likewise, the decrease in CSF NF in the CCSVI positive individuals did not 
reach significance. The 28% increase in the mean ACS value (p=0.021) in the 
CCSVI positive group compared with the CCSVI negative group was 
significant.  
 
Correlation analysis 
Correlation analysis of the MRI data revealed that associations between 
NLVV and the CSF related variables in CCSVI positive subjects were 
generally weaker then in CCSVI negative subjects. For example, Figure 4 
presents a scatter plot of NNF verses NLVV, which in the CCSVI negative 
group exhibited a relatively strong negative correlation (r=-0.686, p<0.001), 
but was lost in the CCSVI positive group (r=-0.103, p=0.674) – a change that 
was significant using a Fisher transformation (p=0.018). Likewise, the strong 
positive correlations between the variables NPF and NLVV (r=0.761, 
p<0.001), and ACS and NLVV (r=0.720, p<0.001) in the CCSVI negative 
group were weaker in the positive group (r=0.404, p=0.086 and r=0.454, 
p=0.051). However, these changes were not significant.  
 
No significant correlation was observed between VHISS score and any of the 
MRI variables for either group, or indeed when both groups were aggregated 
together.  
 
Singular value decomposition cluster analysis 
SVD analysis was performed using just three variables NNF, NPF and NLVV 
(being a derived variable, NF was excluded from the SVD analysis). The 
results of this analysis are presented in Figure 5, which shows a plot of the 
first LSV against the third LSV. The LSVs are composite variables derived 
from the original variables, which have been orthogonalized. This analysis 
separates the CCSVI positive and negative groups relatively well, although 
there is some overlap. The two groups can be broadly separated by the 
straight-line equation: 
 
LSV3 = (2.6  LSV1) + 0.04      (2) 
 
Separating the groups using this equation yields sensitivity and specificity 
scores of 73.7% and 71.9% respectively (p=0.025). The singular values 
associated with the first, second and third LSVs were 11.008, 5.058 and 1.800 
respectively. This indicates that the first LSV explains 80.8% of the variance in 
the system, while the second and third LSVs explain 17.0% and 2.2% of the 
variance, respectively. The composition of the various LSVs is presented in 
Table 3, which shows the linear coefficients that must be applied to the each 
variable in order to reconstruct the respective LSVs. From this it can be seen 
that the coefficients relating to variables NNF and NPF are more dominant in 
the first and third LSVs, whereas the coefficient relating to NLVV is more 
dominant in the second LSV. 
 
  
Discussion 
The subject of CCSVI has been mired with controversy (8,36), with many 
researchers doubting that it is indicative of any pathology (8-13). However, 
there is growing evidence that restricted cerebral venous outflow is a 
phenomenon that is more prevalent in patients with MS, (1-3,5,37), even 
though it is also observed in both healthy individuals (4,6,7) and those with 
other neurological disease (4). While the reasons for this are unclear, it has 
been shown using cervical plethysmography (16,17) that MS patients 
diagnosed with CCSVI exhibit on average a 63.5% increase in the hydraulic 
resistance of the venous pathways from the brain to the heart compared with 
CCSVI negative healthy controls. As such, it raises intriguing questions as to 
whether the increase in aqueductal CSF pulsatility observed in MS patients 
(19) is associated with MS or CCSVI. If increased CSF pulsatility were purely 
an attribute of MS, then one would not expect the phenomenon to be present 
in CCSVI positive healthy controls.  
 
In an attempt to answer the above question, we undertook the present study, 
with the aim of establishing whether or not CCSVI is associated with altered 
intracranial CSF dynamics in healthy individuals with no known neurological 
pathology. From the results in Table 2 and figures 1-3 it appears that CCSVI 
is associated with changes in the aqueductal CSF flow dynamics in healthy 
individuals. In particular, NPF was significantly increased (p=0.008) in the 
CCSVI positive group compared with the CCSVI negative group. NNF was 
also increased, but this was not significant. Likewise, NF decreased in the 
CCSVI positive group, but this was not significant. Comparison between the 
aqueductal CSF flow curves published by Magnano et al (18) for both MS 
patients and healthy controls reveals similar curves to those for the healthy 
CCSVI positive and negative subjects in the present study, suggesting that 
increased aqueductal pulsatility may be primarily associated with impaired 
cerebral venous drainage rather than MS itself. Indeed, the fact that we found 
greatly increased NPF in CCSVI positive healthy individuals, just as Zamboni 
et al (19), Gorucu et al (20), Magnano et al (18) all observed in MS patients, 
further implies that the phenomenon may be biomechanical in nature, rather 
than due to neuronal damage/brain atrophy.  
 
Being encased in a rigid enclosure, the brain employs a complex intracranial 
fluid regulatory mechanism to compensate for increased blood flow during 
systole. This system compensates for the transient increase in arterial blood 
entering the cranium during systole, by displacing an approximately equal 
volume of CSF through the foramen magnum into the spinal column (38). It 
does this by employing a sophisticated windkessel mechanism to smooth 
blood flow through the cerebral capillary bed (39,40); something that appears 
to be sensitive to changes in the cerebral venous system (41-43). Indeed, it 
has been postulated that the venous system plays an important role in 
regulating the dynamics of the intracranial fluid system (44). While the 
mechanisms involved are poorly understood, it can be hypothesized that 
impairment of cerebral venous outflow is likely to induce retrograde 
hypertension in the dural sinuses, as Zamboni et al (45) observed; something 
that might reduce intracranial compliance resulting in altered CSF behaviour 
(43). Evidence supporting this model comes from Luetmer et al (23), Schroth 
& Klose (24), Gideon et al (25), Kim et al (26), El Sankari et al (27) and 
Bradley (28), all of whom found CSF pulsatility in the AoS to be markedly 
greater in NPH patients compared with controls. Given that reduced 
intracranial compliance (29,30,46,47), induced by venous hypertension, is 
thought to be involved in NPH (29,30,48,49), this suggests that impaired 
venous outflow is capable of altering the intracranial CSF dynamics, just as 
we observed in the CCSVI positive healthy individuals. Further evidence to 
support this opinion comes from an interventional study by Zivadinov et al 
(50) in which percutaneous transluminal venous angioplasty was shown to 
reduce aqueductal CSF pulsatility in MS patients diagnosed with CCSVI. 
Although abnormal CSF dynamics and their relation to health verses disease 
status is beyond the scope of this article, it is noticeable that their role in 
neurodegenerative disease is becoming increasingly contemplated (51). 
 
One interesting finding of our study was that CCSVI appeared to be 
associated with a weakening in the correlation between the aqueductal CSF 
pulse variables and NLVV. In healthy individuals there is normally a strong 
correlation between lateral ventricle size and aqueductal CSF flow (52). 
However, in the CCSVI positive group we found the correlations between 
NNF, NPF, ACS and NLVV to be markedly weaker than that in the CCSVI 
negative group. While the reasons for this are not understood, it may be that 
structural changes are at work. Evidence supporting this opinion comes from 
the ensemble mean ACS over the cardiac cycle. This signal is derived by 
dividing each CSF flow signal, by the corresponding CSF velocity signal and 
therefore represents the changes in the AoS area throughout the cardiac 
cycle. The mean ACS is significantly different in both groups, with the mean 
aqueductal area being substantially larger in the CCSVI positive group 
compared with the CCSVI negative group. From this it can be concluded that 
the increased CSF pulsatile flow in the CCSVI positive group is facilitated 
more by enlargement of the AoS than any increase in CSF velocity.     
 
This study is not without limitations. First, the number of the enrolled healthy 
individuals was relatively small and therefore further studies should extend 
our findings using a larger sample size. Second, the diagnosis of CCSVI was 
established only by using DS, while recent studies suggest that increased 
sensitivity and specificity of CCSVI diagnosis, can be achieved using a variety 
of non-invasive and invasive imaging approaches (53). Lastly, the effect of 
altered CSF pulsatility on long-term neurologic outcomes is unknown, and 
only longitudinal studies will be able to provide further insight on this important 
question. 
 
In conclusion, the results of the study suggest that CCSVI is associated with 
intracranial biomechanical changes in healthy individuals. Indeed, such was 
the magnitude of the changes observed that it was relatively easy to 
discriminate, using SVD analysis, between the CCSVI positive and negative 
groups using just the three variables NNF, NPF and NLVV. Given that 
impaired cerebral venous outflow has been shown to be associated with MS 
(16,17), this implies that similar changes in intracranial CSF dynamics 
observed in MS patients (18-20), might be primarily due to the presence of 
CCSVI rather than due to neuronal damage.   
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Tables 
Table 1. Demographic, clinical and whole brain volume characteristics in 
healthy CCSVI positive and negative individuals. 
 CCSVI 
negative 
(n = 32) 
CCSVI 
positive 
(n = 19) 
 
Significance 
(p value) 
Female gender, n (%) 21 (65.6) 9 (47.4) 0.200 
Age in years, mean (SD) 44.3 (14.8) 44.5 (19.1) 0.967 
BMI, mean (SD) 25.7 (5.3) 27.1 (5.3) 0.317 
Hypertension, n (%) 2 (6.3) 0 (0.0) 0.266 
Heart Disease, n (%) 5 (15.6) 2 (10.5) 0.609 
Current Smokers, n (%) 3 (15.0) 0 (0.0) 0.143 
Ever Smokers, n (%) 13 (65.0) 6 (13.0) 0.285 
Type 1 Diabetes, n (%) 0 (0.0) 0 (0.0) 1.000 
VH criteria score, mean (SD) 0.66 (0.48) 2.37 (0.60) <0.001 
VHISS score, mean (SD) 1.31 (1.06) 4.42 (1.43) <0.001 
NBV, mean (SD) 1531.4 
(86.0) 
1509.2 
(74.8) 
0.340 
CCSVI - chronic cerebrospinal venous insufficiency; BMI – body mass index; VH – 
venous hemodynamic; VHISS – venous hemodynamic insufficiency severity score; 
NBV – normalized brain volume.  
The differences between the study groups were tested using the student’s t-test and 
chi-square test. 
 
 
 
Table 2. MRI characteristics in healthy individuals. 
 
 CCSVI 
Negative 
(n = 32) 
CCSVI 
Positive 
(n = 19) 
 
Significance 
(p value) 
 
Effect Size 
Cohen’s d 
NNF (L/beat), mean (SD) -27.6 (19.5) -33.3 (16.9) 0.092 0.304 
NPF (L/beat), mean (SD) 23.6 (22.0) 31.2 (13.6) 0.008 0.391 
NF (L/beat), mean (SD) -4.0 (7.5) -2.1 (8.9) 0.080 0.245 
Mean ACS (mm2), mean (SD) 1.0 (0.5) 1.3 (0.5) 0.021 0.585 
NLVV (mL), mean (SD) 37.5 (21.5) 44.1 (18.3) 0.147 0.322 
 
CCSVI - chronic cerebrospinal venous insufficiency; NNF – net negative CSF flow; 
NPF – net positive CSF flow; NF – net CSF flow (i.e. NNF+NPF); NLVV – normalized 
lateral ventricle volume. 
 
The differences between the study groups were tested using the Mann-Whitney U-
test, and Cohen’s d test. 
 
 
 
 
 
 
 
 
 
Table 3. Composition of respective left singular vectors (LSVs) used in 
the singular value decomposition (SVD). 
 
 NNF NPF NLVV 
First LSV 0.0566 -0.0535 0.0467 
Second LSV -0.0402 0.1015 0.1648 
Third LSV -0.4194 -0.3468 0.1113 
 
NNF – net negative CSF flow; NPF – net positive CSF flow; NLVV – normalized 
lateral ventricle volume. 
 
NB. The values in the table are the linear coefficients that must be applied to the 
component variables in order to reconstruct the respective LSVs. 
 
 
 
 Figures 
 
 
 
 
 
Figure 1. Ensemble mean aqueductal CSF flow signal over a cardiac cycle for 
both the CCSVI positive and negative groups. Between groups difference in 
positive amplitude (p=0.023) and negative amplitude (p=0.044). The phases 
of cycle where the difference between the signals is significant (p<0.050) are 
8-14, 21 and 26-32. (Error bars represent one standard deviation.) 
 
 
 
  
Figure 2. Ensemble mean aqueductal CSF velocity signal over a cardiac cycle 
for both the CCSVI positive and negative groups. Between groups difference 
in positive amplitude (p=0.136) and negative amplitude (p=0.316).  A 
statistically significant difference between the signals (p<0.050) is only 
observed for phase 32 of the cycle. (Error bars represent one standard 
deviation.) 
 
 
 
 
 
 
 
  
 
Figure 3. Sequential ensemble mean ACS over a cardiac cycle for both the 
CCSVI positive and negative groups. Between groups mean ACS, p=0.021. 
The phases of cycle where the difference between the signals is significant 
(p<0.050) are 8-10, 14-15, 18-28 and 30-32. (Error bars represent one 
standard deviation.) 
 
 
 
 
 
 
 
  
Figure 4. Scatter plot of NNF verses NLVV for the CCSVI positive and 
negative groups. CCSVI negative group (r=-0.686; p<0.001) and CCSVI 
positive group (r=-0.103; p=0.674). 
 
 
 
 
 
 
 
 
 
 
  
Figure 5. Singular value decomposition (SVD) cluster analysis results (derived 
using the three variables NNF, NPF and NLVV) (p=0.025). 
 
 
 
 
